Ethiodised oil

Drug Profile

Ethiodised oil

Alternative Names: Ethiodol; Lipiodol

Latest Information Update: 31 May 2016

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Guerbet
  • Class Antineoplastics; Contrast media; Diagnostic agents; Infertility therapies
  • Mechanism of Action Diagnostic imaging enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer metastases; Hepatocellular carcinoma; Lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2015 Guerbet signs an agreement with Beijing Ke Yuan Xinhai Pharmaceuticals to distribute and commercialise Ethiodised oil (Lipiodol®) in China
  • 10 Apr 2014 Registered for Hepatocellular carcinoma (diagnosis) and Diagnostic imaging in USA (Intrahepatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top